Disruptive Pharma sells GTX platform to Aurelia Invest unit
Disruptive Pharma has agreed to sell its GTX platform, including peptide programs and lead candidate GTX-86, to a wholly owned subsidiary of Aurelia Invest. The deal includes a modest upfront cash payment, with Disruptive Pharma retaining royalties, future milestone payments, and a share of proceeds from any future sale or out-licensing of the platform.
Story updates
06:08:15 AM UTC
SquawkNews
Sept 22 (Reuters) — Disruptive Pharma AB (publ): Agrees To Sell Gtx Platform To Aurelia Invest Ab Subsidiary Consideration Includes Minor Initial Cash Payment And Future Performance-based Payments Payments Based On Milestones Including First Human Dosing And Market Approval Source text:... Further company coverage: DPHAR.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;)